Company Description
Sutro Biopharma, Inc. operates as a oncology company.
The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+.
Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer.
The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors, such as triple negative breast cancer, non-small cell lung cancer, and ovarian cancer, as well as hematological cancers.
Sutro Biopharma, Inc. has collaboration and license agreements with Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; Ipsen to develop and commercialize STRO-003, an ADC targeting ROR1; and Astellas Pharma Inc. to develop immunostimulatory ADC.
The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2003 |
| IPO Date | Sep 27, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 310 |
| CEO | Jane Chung |
Contact Details
Address: 111 Oyster Point Boulevard South San Francisco, California 94080 United States | |
| Phone | 650 881 6500 |
| Website | sutrobio.com |
Stock Details
| Ticker Symbol | STRO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001382101 |
| CUSIP Number | 869367102 |
| ISIN Number | US8693671021 |
| Employer ID | 45-2441988 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jane Chung R.Ph. | Chief Executive Officer and Director |
| Edward C. Albini M.B.A | Chief Financial Officer and Secretary |
| Dr. James R. Swartz DSc, Ph.D., Sc.D. | Founder |
| Dr. Venkatesh Srinivasan Ph.d. | Chief Technical Operations Officer |
| Dr. Hans-Peter Gerber Ph.D. | Chief Scientific Officer |
| David Pauling J.D., M.A. | Chief Administrative Officer and General Counsel |
| Linda A. Fitzpatrick | Chief People and Communications Officer |
| Dr. Anne Elizabeth Borgman-Hagey M.D. | Chief Medical Officer |
| Dr. Barbara Leyman Ph.D. | Chief Business Officer |
| Regina Cheng | Vice President and Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 8, 2025 | 10-Q | Quarterly Report |
| May 8, 2025 | 8-K | Current Report |
| Apr 25, 2025 | ARS | Filing |
| Apr 25, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 25, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 17, 2025 | SCHEDULE 13G/A | Filing |
| Apr 14, 2025 | PRE 14A | Other preliminary proxy statements |
| Apr 14, 2025 | 8-K | Current Report |
| Apr 4, 2025 | SCHEDULE 13G | Filing |
| Mar 13, 2025 | 10-K | Annual Report |